Coherus Oncology (CHRS) vs Cardiff Oncology (CRDF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cardiff Oncology (CRDF) has outperformed Coherus Oncology (CHRS) over the past year, losing 58.0% versus a loss of 68.1%. Over five years, CRDF leads with a -84.8% price change compared with -98.0% for CHRS. Cardiff Oncology is the larger company by market cap ($66.3 million vs $57.1 million), about 1.2 times the size, while Coherus Oncology is growing revenue faster (+59.8% vs -13.2%).
Coherus Oncology converts more of its revenue into profit, with a net margin of 398.4% versus -7732.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | CRDF |
|---|---|---|
| Share price | $0.3698 | $0.8528 |
| Market cap | $57.15M | $66.34M |
| 1-day change | -4.47% | -4.46% |
| YTD return | -73.96% | -69.65% |
| 1-year return | -68.12% | -57.99% |
| 5-year return | -97.99% | -84.80% |
| EPS (TTM) | $-1.12 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $42.17M | $593.00K |
| Revenue growth (YoY) | +59.81% | -13.18% |
| Net income (latest FY) | $168.02M | $-45.85M |
| Gross margin | 67.24% | — |
| Operating margin | -429.51% | -8256.32% |
| Net margin | 398.43% | -7732.04% |
| 52-week high | $2.62 | $3.31 |
| 52-week low | $0.3628 | $0.71 |
| Distance from 52-week high | -85.86% | -74.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1995.73% | +581.29% |
| Average volume | 1.80M | 1.01M |
| Shares outstanding | 154.54M | 77.80M |
| Employees | 144 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDF has outperformed CHRS by 10.1 percentage points over the past year.
- Coherus Oncology is more profitable, keeping 398.4 cents of every revenue dollar as net income versus -7732.0 cents for Cardiff Oncology.
- Coherus Oncology grew revenue faster in its latest fiscal year (+59.81% vs -13.18%).
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
CHRS vs CRDF FAQ
Which is bigger, Coherus Oncology or Cardiff Oncology?
Cardiff Oncology (CRDF) is larger, with a market capitalization of $66.34M compared with $57.15M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, CHRS or CRDF?
CRDF returned -57.99% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Cardiff Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.